Rosetta Genomics mesothelioma test licensed to Prometheus Labs

"Rosetta Genomics announced earlier this year that its microRNA-based mesothelioma test, miRview™ meso, was being produced in the company’s labs in Philadelphia, Pennsylvania and was available to physicians. See related story. The test represented a significant step forward in allowing physicians to easily and definitively distinguish between pleural mesothelioma and lung cancer. ..." (2009-5-1)
Read more...